Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.22 +0.39 (+0.82%)
Streaming Delayed Price Updated: 9:38 AM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,815
Open 48.14
Bid (Size) 48.20 (1)
Ask (Size) 48.21 (8)
Prev. Close 47.83
Today's Range 48.11 - 48.23
52wk Range 42.63 - 55.72
Shares Outstanding 1,250,690,553
Dividend Yield 3.95%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from... 
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-3.56%
-3.56%
1 Month
+3.45%
+3.45%
3 Month
-1.13%
-1.13%
6 Month
+2.20%
+2.20%
1 Year
-6.84%
-6.84%

More News

Read More
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
VeeCon 2024 Speakers Announced: X CEO Linda Yaccarino, Content Creator Khaby Lame, Gary Vee Among Special Guests To Appear At Festival That Combines Business, Pop Culture, Web3
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why Vaccine Stocks Rallied This Week
Via The Motley Fool
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
Via InvestorPlace
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Via Benzinga
Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M
Via Benzinga
3 Biotech Stocks to Buy Now: May 2024
Via InvestorPlace
3 Things You Need to Know If You Buy Novavax Today
Via The Motley Fool
ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Roaring Kitty’s Rally Cry: 3 Meme Stocks to Pounce On Now
Via InvestorPlace
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
Via The Motley Fool
Could Novavax Become the Next Moderna?
Via The Motley Fool
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
Via Benzinga
Is DoubleVerify’s 39% Haircut a Buying Opportunity?
Via MarketBeat
Topics Artificial Intelligence Fraud Malware
Exposures Artificial Intelligence Information Security Legal
3 Stocks Under $2 That Can Trade in Double Digits by 2025
Via InvestorPlace
Novavax Stock Just Tripled. Is It Too Late to Buy?
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Cheap Biotech Stocks to Buy Now: May 2024
Via InvestorPlace
Exposures Product Safety
3 Meme Stocks That Are Likely to Crater in 2024
Via InvestorPlace
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.